ImmunityBio, Inc. IBRX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 99.3%0.0pp | 99.3%-0.2pp | 99.6%-0.1pp | 99.7%-0.2pp | 99.8%-0.2pp | |
| Operating margin | -185.4%+40.6pp | -226%+89.8pp | -315.8%+188pp | -504.2%+500pp | -1,003.8%+1,330pp | |
| Net margin | -606.2%-296pp | -310.2%+112pp | -422.3%+226pp | -648.6%+662pp | -1,310.3%+1,494pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×0.0× | 0.3×+0.1× | 0.2×+0.1× | 0.1×0.0× | 0.1×+0.1× | |
| Liquidity | ||||||
| Current ratio | 6.7×+1.6× | 5.1×-0.7× | 5.8×+1.7× | 4.1×+1.9× | 2.2×-1.1× | |
| Per Share | ||||||
| Book value per share | -$0.85-55.7% | -$0.54+1.8% | -$0.55+13.8% | -$0.64+7.3% | -$0.69+0.7% | |
| Valuation | ||||||
| Market capitalization | $7.92B+306% | $1.95B-16.1% | $2.33B-5.6% | $2.46B-4.1% | $2.57B+37.4% | |
| Price / sales | 56.2×+39.0× | 17.2×-11.0× | 28.2×-15.3× | 43.5×-38.8× | 82.3×-44.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ImmunityBio, Inc.'s profit margins?
- ImmunityBio, Inc. (IBRX) runs a 99.3% gross margin and a -185.4% operating margin, with a -606.2% net margin.
- Where do ImmunityBio, Inc.'s ratios come from?
- Every ratio is computed from ImmunityBio, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
